Author + information
- Received December 19, 1983
- Revision received February 6, 1984
- Accepted March 16, 1984
- Published online August 1, 1984.
- John U. Doherty, MD*,1,2,
- Harvey L. Waxman, MD, FACC1,
- Michael G. Kienzle, MD1,3,
- Dennis M. Cassidy, MD1,4,
- Francis E. Marchlinski, MD1,
- Alfred E. Buxton, MD1,5 and
- Mark E. Josephson, MD1,6
- ↵*Address for reprints: John U. Doherty, MD, Room 654 Ravdin, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania 19104.
The electrophysiologic effects and response to programmed ventricular stimulation of intravenous propafenone, an experimental antiarrhythmic agent, were studied in a group of 14 patients with both clinical and induced sustained ventricular tachycardia. Twelve of the 14 patients had not responded to conventional antiarrhythmic drug therapy. Propafenone had no significant effect on sinus cycle length (836 ± 170 ms before and 750 ± 124 ms after propafenone), P wave duration (108 ± 24 ms before and 106 ± 23 ms after propafenone) or PR interval (181 ± 45 ms before and 194 ± 53 ms after propafenone). QRS duration and ventricular effective refractory periods increased significantly (109 ± 20 to 130 ± 21 ms and 235 ± 24 to 256 ± 19 ms, respectively).
Ventricular tachycardia remained inducible or occurred spontaneously in 13 of 14 patients after propa- fenone administration. Neither mode of initiation nor mode of termination of ventricular tachycardia was predictably altered. Additional forms of ventricular tachycardia were seen in six patients. Cycle length of ventricular tachycardia was 303 ± 73 ms before and 346 ± 143 ms after propafenone (p = NS).
In conclusion, intravenous propafenone does not significantly affect sinus rate, intraatrial conduction or atrioventricular conduction. Ventricular refractoriness and intraventricular conduction are prolonged. The mode of initiation, mode of termination and ventricular tachycardia cycle length are not predictably altered, but ventricular tachycardia occasionally occurs spontaneously after propafenone. Intravenous propafenone rarely prevents induction of ventricular tachycardia in patients with sustained ventricular tachycardia refractory to conventional antiarrhythmic agents.
- Received December 19, 1983.
- Revision received February 6, 1984.
- Accepted March 16, 1984.
- American College of Cardiology Foundation